Want to see TXMD full AI Analyst Report?
Top Page
TherapeuticsMD
(NASDAQ:TXMD)
Select Model
Select Model
Rating:55Neutral
Price Target:
$2.50
▲(9.65% Upside)
Action:Reiterated
Date:08/26/26
The score is driven primarily by improving financial stability (positive free cash flow and manageable leverage) but is held back by weak operating performance (small, declining revenue and negative EBIT/EBITDA). Technicals are moderately supportive due to an uptrend, though the overbought RSI adds near-term risk. Valuation remains unattractive/unclear given the negative P/E, and corporate developments add uncertainty due to the strategic alternatives review.
Positive Factors
Positive Free Cash Flow
Positive operating and free cash flow mark a meaningful recovery from deeply negative cash generation in 2023. Sustained cash production could support ongoing royalty operations and reduce reliance on external financing, although coverage remains incomplete.
Negative Factors
Small and Declining Revenue Base
The limited and declining revenue base constrains operating leverage and leaves the company dependent on a small set of licensed products or arrangements. Continued weakness could reduce cash generation and make it harder to fund operations or develop new assets.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive Free Cash Flow
Positive operating and free cash flow mark a meaningful recovery from deeply negative cash generation in 2023. Sustained cash production could support ongoing royalty operations and reduce reliance on external financing, although coverage remains incomplete.
Read all positive factors
TherapeuticsMD (TXMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$25.70M
Dividend YieldN/A
Average Volume (3M)310.58K
Price to Earnings (P/E)―
Beta (1Y)1.06
Revenue Growth27.78%
EPS Growth52.88%
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding11,574,362
10 Day Avg. Volume897,126
30 Day Avg. Volume310,579
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)0.70
Price to Sales (P/S)6.24
P/FCF Ratio7.78
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.17
Revenue Forecast (FY)$9.30M
TherapeuticsMD Business Overview & Revenue Model
Company Description
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estr...
How the Company Makes Money
TherapeuticsMD has generated revenue primarily through out-licensing/partnering arrangements for its product portfolio rather than through building a fully integrated, long-term direct commercial sales model. Under these types of agreements, the c...
TherapeuticsMD Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
64
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.27M | 3.02M | 1.76M | 1.30M | 69.96M | 2.57M |
| Gross Profit | 2.94M | 3.02M | 1.76M | 1.30M | 68.57M | 1.17M |
| EBITDA | -4.20M | -3.02M | -3.56M | -7.60M | 11.86M | -78.84M |
| Net Income | -217.00K | -569.00K | -2.18M | -10.28M | 112.00M | -172.41M |
Balance Sheet | ||||||
| Total Assets | 37.53M | 37.66M | 38.82M | 43.31M | 90.46M | 169.47M |
| Cash, Cash Equivalents and Short-Term Investments | 9.19M | 7.48M | 5.06M | 4.33M | 38.07M | 64.91M |
| Total Debt | 5.56M | 6.10M | 7.17M | 8.01M | 8.76M | 197.69M |
| Total Liabilities | 10.40M | 10.78M | 11.45M | 14.02M | 55.31M | 263.09M |
| Stockholders Equity | 27.13M | 26.88M | 27.37M | 29.29M | 35.14M | -93.62M |
Cash Flow | ||||||
| Free Cash Flow | 3.12M | 2.42M | 732.00K | 0.00 | -4.43M | -147.84M |
| Operating Cash Flow | 3.12M | 2.42M | 732.00K | -48.14M | -4.08M | -147.81M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 223.48M | -2.22M |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | 3.15M | -235.21M | 134.67M |
TherapeuticsMD Technical Analysis
Positive
2.28
Price Trends
2.06
Positive
2.06
Positive
2.05
Positive
Market Momentum
0.04
Negative
64.62
Neutral
75.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TXMD, the sentiment is Positive. The current price of 2.28 is above the 20-day moving average (MA) of 2.10, above the 50-day MA of 2.06, and above the 200-day MA of 2.05, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 64.62 is Neutral, neither overbought nor oversold. The STOCH value of 75.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TXMD.
TherapeuticsMD Risk Analysis
TherapeuticsMD disclosed 49 risk factors in its most recent earnings report. TherapeuticsMD reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
TherapeuticsMD Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $25.70M | -118.09 | 0.66% | ― | 27.78% | 52.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Underperform | $418.57K | >-0.01 | -453.74% | ― | ― | ― | |
39 Underperform | $3.83M | -0.33 | 5740.28% | ― | ― | ― | |
37 Underperform | $24.04M | -0.52 | -148.91% | ― | -18.24% | -2264.65% |
* Healthcare Sector Average
TXMD
TherapeuticsMD
2.22
1.11
100.00%
PRPH
Prophase Labs
0.02
-3.36
-99.35%
RDHL
RedHill Biopharma
0.66
-0.69
-51.04%
AYTU
Aytu BioScience
2.25
-0.10
-4.26%
GELS
Gelteq Limited
0.56
-0.70
-55.67%
TherapeuticsMD Corporate Events
Business Operations and StrategyFinancial Disclosures
TherapeuticsMD Q2 Results and Strategic Alternatives Review
Negative
Aug 11, 2026
On August 11, 2026, TherapeuticsMD reported second quarter 2026 results for the period ended June 30, highlighting net income from continuing operations of $164 thousand, down from $545 thousand a year earlier. License revenue slipped to $869 thou...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.